Navigation Links
Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
Date:11/13/2008

STOCKHOLM, November 13 /PRNewswire/ -- Karolinska Development AB, a Swedish investment company using a unique, highly cost effective model to commercialize internationally renowned life science announced today the appointment of Dr. Carl Harald Janson as investment manager.

"Carl Harald is an outstanding addition to our management team," stated Conny Bogentoft, Chief Executive Officer of Karolinska Development. "His extensive experience within the medical, pharmaceutical and investment arenas will provide an invaluable perspective for our future growth". His former activities have included work as Medical Adviser for Clinical Research and Director of Immunology for Preclinical R&D at Astra Arcus AB, Senior Financial Analyst at Hagstromer & Qviberg Fondkommission AB and Danske Securities, Danske Bank in Stockholm. He moved into fund management with companies including Carnegie Investment Bank AB.

He is a Medical Doctor holding a PhD. from Karolinska Institutet in Stockholm and qualified as a Certified European Financial Analyst at Stockholm School of Economics.

Carl Harald will take responsibility for the Karolinska Development pharma project portfolio. Bringing with him a vast network of individuals with both management and operational skills, which will further strengthen the cost effective business model used by Karolinska Development.

About Karolinska Development

Karolinska Development is a Swedish investment company using a unique, highly cost effective model to commercialize internationally renowned life science innovations. Professionals in business development and management, supported by a network of experienced technical specialists, ensure fast and efficient development. This enables Karolinska Development to rapidly build value in high risk opportunities, through long term lead investor position from seed stage; developing the medical products of the future.

Karolinska Development's office is located at the Karolinska Institute Science Park, Sweden http://www.karolinskadevelopment.com
More about Karolinska Development: http://www.karolinskadevelopment.com

Contact: Conny Bogentoft, CEO

Tel: +46(0)8-524861-43

e-mail: info@karolinskadevelopment.com


'/>"/>
SOURCE Karolinska Development AB
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
4. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
5. Global Experts Explore Entire Spectrum of Aids Vaccine Development
6. Vical Names Andrew de Guttadauro Vice President, Corporate Development
7. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
8. SemBioSys updates Apo AI development program
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... presented demonstrating the role of the Breast Cancer ... stage, ER+ breast cancer are most at-risk for ... therapy. Data include results from three studies advancing ... provide information related to tumor biology and inform ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... data bioInformatics portal. In response to client demand KbioBox developed a sophisticated “3 ... biodesign program. Both are accessible from KBioBox’s new website, https://www.kbiobox.com/ ...
(Date:12/8/2016)... N.J. , Dec. 8, 2016  Soligenix, ... late-stage biopharmaceutical company focused on developing and commercializing ... an unmet medical need, announced today the long-term ... with SGX942 (dusquetide), a first-in-class Innate Defense Regulator ... in head and neck cancer patients undergoing chemoradiation ...
Breaking Biology Technology:
(Date:12/7/2016)... 7, 2016   Avanade is helping Williams ... teams in history, exploit biometric data in order to ... maintain the competitive edge against their rivals after their ... Avanade has worked with Williams during the 2016 ... data (heart rate, breathing rate, temperature and peak acceleration) ...
(Date:12/6/2016)... , Dec. 6, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... jointly announced today a five (5) year funding ... agreement to expand the rehabilitation and reentry support ... PEP History Established in 2004, the Prison Entrepreneurship ...
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we spend ... recovery so we need to do it well. Inadequate sleep levels have been found ... pressure, stroke, diabetes, and even cancer. Maybe now is the best time ... could help them to manage their sleep quality? Continue ... ...
Breaking Biology News(10 mins):